>>> USGapping up

Gapping up
In reaction to strong earnings/guidance:

KPTI +29.6%, SITO +17.3%, TLRD +14.2%, SFS +11.6%, FIVN +11.1%, HIIQ +10.8%, HIVE +10.2%, ATSG +9.5%, TGB +8.9%, BCOR +8.5%, DATA +8.4%, FORM +8.4%, WTI +8.4%, AIRG +8.2%, AOSL +8%, FIT +7.4%, XPO +6.6%, PCOM +6.4%, ARWR +5.8%, RAIL +5.6%, GNCA +5.6%, TVIA +5.4%,EBIO +5.4%, PIP +5%, SQ +5%, LGCY +4.9%, GTN +4.8%, GMED +4.7%,EMKR +4.7%, NVDQ +4.6%, HDSN +4.4%, BRKR +3.4%, HSBC +3.4%, HK +3%, OSUR +3%, HMHC +3%, VVUS +2.9%, ARRS +2.8%, SRI +2.6%, EXTR +2.4%, MFC +2.3%, EZPW +2.3%, MTDR +2.2%, ALB +2.2%, HZN +2.1%,LHCG +2.1%, ICPT +2.1%, OMF +2%, CLVS +1.9%, COT +1.8%, GPN +1.8%,GLUU +1.6%, INCY +1.6%, WPX +1.5%, CLR +1.4%, RDS.A +1.4%, TWO +1.3%, IO +1.2%, AGI +1.2%, PRU +1.1%, AIG +1.1%, STMP +1.1%, JCAP +1%, .

Other news:

APHB +20.8% (still checking; light volume)
SCON +14.6% (10% owner Director Kopp disclosed the purchase of 200K shares )
MNKD +12% (Mannkind and One Drop enter into a collaborative agreement)
CLSN +8.2% (announces updated date from its Phase Ib dose escalating clinical trial combining GEN-1 with the standard of care)
RXDX +6.5% (prices 12.5 million share common stock offering at $6.15/share; gross proceeds expected to be $76.9 mln)
KPTI +5.4% (Karyopharm Therapeutics and Anivive Lifesciences sign exclusive global license agreement for verdinexor; KPTI to receive $1 mln upfront payment and eligible to receive up to $43.5 mln in future milestones, plus royalties )
SGMO +5.4% (granted orphan designation by the FDA for its compound for the treatment of hemophilia A)
CTRV +5% (announces it is developing a second-generation formulation of TXL)

Analyst comments: